Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Dold

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Nature Communications|August 18, 2021
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concernDonal T Skelly, Adam C Harding, Javier Gilbert-Jaramillo, et al.
Lancet (London, England)|September 4, 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, et al.
Clinical and Experimental Immunology|February 2, 2023
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trialsMerryn Voysey, Amy Flaxman, Jeremy Aboagye, et al.
Nature Medicine|May 22, 2021
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
Nature Medicine|December 18, 2020
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
Cell|March 17, 2021
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced seraDaming Zhou, Wanwisa Dejnirattisai, Piyada Supasa, et al.
The Lancet. Microbe|November 15, 2021
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort studyAdrienn Angyal, Stephanie Longet, Shona C Moore, et al.
Wellcome Open Research|December 8, 2020
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virusMonique I Andersson, Carolina V Arancibia-Carcamo, Kathryn Auckland, et al.
JCI Insight|May 24, 2022
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronavirusesAnna L McNaughton, Robert S Paton, Matthew Edmans, et al.
Nature Medicine|December 18, 2020
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Nature Communications|August 18, 2021
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concernDonal T Skelly, Adam C Harding, Javier Gilbert-Jaramillo, et al.
Lancet (London, England)|September 4, 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, et al.
Clinical and Experimental Immunology|February 2, 2023
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trialsMerryn Voysey, Amy Flaxman, Jeremy Aboagye, et al.
Nature Medicine|May 22, 2021
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
Nature Medicine|December 18, 2020
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
Cell|March 17, 2021
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced seraDaming Zhou, Wanwisa Dejnirattisai, Piyada Supasa, et al.
The Lancet. Microbe|November 15, 2021
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort studyAdrienn Angyal, Stephanie Longet, Shona C Moore, et al.
Wellcome Open Research|December 8, 2020
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virusMonique I Andersson, Carolina V Arancibia-Carcamo, Kathryn Auckland, et al.
JCI Insight|May 24, 2022
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronavirusesAnna L McNaughton, Robert S Paton, Matthew Edmans, et al.
Nature Medicine|December 18, 2020
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, et al.
Pageof 7